Needham Starts Coverage on Solid Biosciences with Buy Rating
Needham initiates Buy on Solid Biosciences with $16 target, highlighting potential of SGT-003 gene therapy amid concerns over Sarepta’s Elevidys safety.
/ 1664 items
#XY↓
Axogen Stock Soars on FDA Approval for Nerve Repair Treatment
Axogen shares jumped 7% in premarket trading after FDA approved its Avance nerve repair treatment for adults and children, strengthening its market position.
Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.
Incannex IHL-42X Secures FDA Fast Track for OSA Treatment
Incannex's oral drug (IHL-42X) for serious sleep apnea (OSA) got FDA Fast Track status to speed up its development and potential approval.
Guggenheim Downgrades Black Diamond Therapeutics on Silevertinib Concerns
Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.